Skip to main content Help with accessibility Skip to main navigation

September 2021 updates to the website

The website has now been updated following September's LSCMMG

The following guidelines have been added/updated:

 Vitamin D position statement- Updated 

The following medicines have been added/updated:

Adalimumab, etanercept, infliximab and abatacept  (NICE TA715) - for treating moderate rheumatoid arthritis after conventional DMARDs have failed

Ixekizumab (NICE TA718) - for treating axial spondyloarthritis

Secukinumab (NICE TA719) - for treating non-radiographic axial spondyloarthritis

The following Items will be updated and added to the website following the next Strategic Commissioning Committee (SCC) Meeting:

Idarucizumab - adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.